381 related articles for article (PubMed ID: 17420697)
1. Intravitreal bevacizumab (Avastin) for retinal angiomatous proliferation.
Meyerle CB; Freund KB; Iturralde D; Spaide RF; Sorenson JA; Slakter JS; Klancnik JM; Fisher YL; Cooney MJ; Yannuzzi LA
Retina; 2007; 27(4):451-7. PubMed ID: 17420697
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration.
Spaide RF; Laud K; Fine HF; Klancnik JM; Meyerle CB; Yannuzzi LA; Sorenson J; Slakter J; Fisher YL; Cooney MJ
Retina; 2006 Apr; 26(4):383-90. PubMed ID: 16603955
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal bevacizumab as primary treatment for retinal angiomatous proliferation: twelve-month results.
Gharbiya M; Allievi F; Recupero V; Martini D; Mazzeo L; Gabrieli CB
Retina; 2009 Jun; 29(6):740-9. PubMed ID: 19516116
[TBL] [Abstract][Full Text] [Related]
4. Sequential combined treatment with intravitreal bevacizumab and photodynamic therapy for retinal angiomatous proliferation.
Viola F; Mapelli C; Villani E; Tresca Carducci F; Vezzola D; Ratiglia R
Eye (Lond); 2010 Aug; 24(8):1344-51. PubMed ID: 20339389
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal bevacizumab (avastin) treatment of retinal angiomatous proliferation.
Ghazi NG; Knape RM; Kirk TQ; Tiedeman JS; Conway BP
Retina; 2008 May; 28(5):689-95. PubMed ID: 18463511
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab (avastin) therapy for idiopathic macular telangiectasia type II.
Kovach JL; Rosenfeld PJ
Retina; 2009 Jan; 29(1):27-32. PubMed ID: 18936721
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
Retina; 2007; 27(4):432-8. PubMed ID: 17420694
[TBL] [Abstract][Full Text] [Related]
9. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab (Avastin) treatment in patients with retinal angiomatous proliferation.
Joeres S; Heussen FM; Treziak T; Bopp S; Joussen AM
Graefes Arch Clin Exp Ophthalmol; 2007 Nov; 245(11):1597-602. PubMed ID: 17437123
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion.
Rabena MD; Pieramici DJ; Castellarin AA; Nasir MA; Avery RL
Retina; 2007; 27(4):419-25. PubMed ID: 17420692
[TBL] [Abstract][Full Text] [Related]
12. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
[TBL] [Abstract][Full Text] [Related]
13. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
Rich RM; Rosenfeld PJ; Puliafito CA; Dubovy SR; Davis JL; Flynn HW; Gonzalez S; Feuer WJ; Lin RC; Lalwani GA; Nguyen JK; Kumar G
Retina; 2006; 26(5):495-511. PubMed ID: 16770255
[TBL] [Abstract][Full Text] [Related]
14. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up.
Arevalo JF; Fromow-Guerra J; Quiroz-Mercado H; Sanchez JG; Wu L; Maia M; Berrocal MH; Solis-Vivanco A; Farah ME;
Ophthalmology; 2007 Apr; 114(4):743-50. PubMed ID: 17398322
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal bevacizumab for refractory pseudophakic cystoid macular edema: the Pan-American Collaborative Retina Study Group results.
Arevalo JF; Maia M; Garcia-Amaris RA; Roca JA; Sanchez JG; Berrocal MH; Wu L;
Ophthalmology; 2009 Aug; 116(8):1481-7, 1487.e1. PubMed ID: 19545901
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study.
Costa RA; Jorge R; Calucci D; Melo LA; Cardillo JA; Scott IU
Retina; 2007 Feb; 27(2):141-9. PubMed ID: 17290194
[TBL] [Abstract][Full Text] [Related]
17. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration.
Emerson MV; Lauer AK; Flaxel CJ; Wilson DJ; Francis PJ; Stout JT; Emerson GG; Schlesinger TK; Nolte SK; Klein ML
Retina; 2007; 27(4):439-44. PubMed ID: 17420695
[TBL] [Abstract][Full Text] [Related]
18. Short-term safety and efficacy of intravitreal bevacizumab for pseudophakic cystoid macular edema.
Barone A; Russo V; Prascina F; Delle Noci N
Retina; 2009 Jan; 29(1):33-7. PubMed ID: 18854783
[TBL] [Abstract][Full Text] [Related]
19. Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion.
Pai SA; Shetty R; Vijayan PB; Venkatasubramaniam G; Yadav NK; Shetty BK; Babu RB; Narayana KM
Am J Ophthalmol; 2007 Apr; 143(4):601-6. PubMed ID: 17306753
[TBL] [Abstract][Full Text] [Related]
20. Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up.
Wu L; Arevalo JF; Roca JA; Maia M; Berrocal MH; Rodriguez FJ; Evans T; Costa RA; Cardillo J;
Retina; 2008 Feb; 28(2):212-9. PubMed ID: 18301025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
